Table 1.
Basic characteristics of the included studies.
| Number | Author | Year | Country | Research type | Medication |
|---|---|---|---|---|---|
| 1 | Zhenfei Ou | 2021 | China | Case-control | Dapagliflozin |
| 2 | Nur Aisyah Zainordin | 2019 | Malaysia | Case-control | Dapagliflozin |
| 3 | Xiaoqing Mo | 2019 | China | Case-control | Dapagliflozin |
| 4 | Sachiko Hattori | 2018 | Japan | Case-control | Engligliflozin |
| 5 | Xiaoying Xia | 2020 | China | Case-control | Dapagliflozin |
| 6 | Daxiang Huang | 2020 | China | Case-control | Dapagliflozin |
| 7 | Wenjun Zhang | 2021 | China | Case-control | Engligliflozin |
| 8 | Nedogoda S.V | 2021 | Russia | Case-control | Engligliflozin |
| 9 | Aki Okamoto | 2016 | Japan | Prospective cohort | Dapagliflozin |
| 10 | Ryotaro Bouchi | 2017 | Japan | Prospective cohort | Luseogliflozin |
| 11 | Hiroshi Tobita | 2017 | Japan | Prospective cohort | Dapagliflozin |
| 12 | Akira Sezai | 2019 | Japan | Prospective cohort | Canagliflozin |
| 13 | Takeshi Osono | 2018 | Japan | Prospective cohort | Canagliflozin |